Skip to main content

Table 3 Responses to sorafenib treatment

From: Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

 

N = 94

Complete response

0 (0)

Partial response

2 (2)

Stable disease

28 (29)

Progressive disease

64 (69)

DCR (95% CI)

21.9% (23.7–42.8)

  1. Abbreviations: DCR disease control rate, CI confidence interval.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us